Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Sep;48(3):241-245.
doi: 10.1007/s12029-017-9960-7.

Cancer Stem Cells in Hepatocellular Carcinoma

Affiliations
Review

Cancer Stem Cells in Hepatocellular Carcinoma

Tamer Yagci et al. J Gastrointest Cancer. 2017 Sep.

Abstract

Background: Hepatocellular carcinoma is one of the most common cancers and the second leading cause of cancer-related deaths worldwide. Only a small proportion of patients benefit from curative treatment and the prognosis is very poor for the majority of cases due to late presentation, resistance to chemotherapy and high recurrence rate. In recent years, progress in stem cell biology allowed us to explain that hierarchically organized cancer stem cells (CSCs) drive histological and functional heterogeneity of hematological malignancies and solid tumors.

Methods and results: Also referred to as tumor-initiating cells, CSCs have been isolated from both hepatocellular carcinoma (HCC) cell lines and primary tumors by using hepatic progenitor markers. Although there is still no consensus on cancer stem cell phenotype in HCC, single or combined use of CSC markers defines a minor population of tumor cells with the capacity of self-renewing and the ability to recapitulate the original tumor heterogeneity.

Conclusions: This review focuses on the biological features of CSCs and their potential as diagnostic/prognostic tools and therapeutic targets in HCC.

Keywords: Cancer stem cell markers; Cancer stem cells; Hepatocellular carcinoma; Metastasis; Tumor heterogeneity; Tumor recurrence.

PubMed Disclaimer

References

    1. J Clin Invest. 2010 Sep;120(9):3326-39 - PubMed
    1. Am J Respir Cell Mol Biol. 2011 Mar;44(3):377-83 - PubMed
    1. Cancer Res. 2007 Feb 1;67(3):1030-7 - PubMed
    1. Gastroenterology. 2007 Jun;132(7):2542-56 - PubMed
    1. Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10158-63 - PubMed

LinkOut - more resources